Since MyD88L265P oncogenic signaling in lymphoma cells leads to the activation of the NF-κB pathway, we hypothesized that the inhibition of NF-κB signaling could prevent the observed transcriptional changes in MyD88L265P-expressing cells. Here, NFKB1 is linked to lymphoma.